Table 3.
Perioperative and pathological outcomes
| Parameter | PPTP-SP (n = 18) | TP (n = 38) | P value |
| Perioperative outcomes | |||
| Operative time (h), median (IQR) | 6.7 (6.6-8.2) | 7.3 (6.8-8.6) | 0.076 |
| Estimated blood loss (mL), median (IQR) | 550 (400-800) | 600 (500-1200) | 0.386 |
| Red cells transfusion (mL), median (IQR) | 200 (200-600) | 400 (200-1000) | 0.249 |
| Resection of PV/SMV, n (%) | 11 (61.1) | 21 (55.3) | 0.680 |
| Overall morbidity, n (%) | 7 (38.9) | 13 (34.2) | 0.733 |
| Major complications, n (%) | 1 (5.6) | 3 (7.9) | 0.751 |
| Delayed gastric emptying, n (%) | 2 (11.1) | 4 (10.5) | 0.947 |
| Pulmonary disease, n (%) | 3 (16.7) | 4 (10.5) | 0.516 |
| Chyle leakage, n (%) | 1 (5.6) | 3 (7.9) | 0.751 |
| Postpancreatectomy hemorrhage, n (%) | 1 (5.6) | 2 (5.3) | 0.964 |
| Abdominal collection, n (%) | 1 (5.6) | 1 (2.6) | 0.582 |
| Arrhythmia, n (%) | 2 (11.1) | 3 (7.9) | 0.693 |
| Biliary leakage, n (%) | 0 (0.0) | 0 (0.0) | - |
| Biochemical leak, n (%) | 2 (11.1) | 0 (0.0) | 0.099 |
| Grade B or C pancreatic fistula, n (%) | 0 (0.0) | 0 (0.0) | - |
| Reoperation, n (%) | 0 (0.0) | 0 (0.0) | - |
| Morality, n (%) | 0 (0.0) | 0 (0.0) | - |
| Readmission, n (%) | 1 (5.6) | 3 (7.9) | 0.751 |
| Postoperative staying (d), median (IQR) | 9.5 (7-16) | 11.5 (9-17.5) | 0.286 |
| Pathological outcomes | |||
| Histology, n (%) | 0.153 | ||
| PDAC without IPMN | 18 (100.0) | 34 (89.5) | |
| PDAC concomitant with IPMN | 0 (0.0) | 4 (10.5) | |
| Differentiation, n (%) | 0.829 | ||
| High | 1 (5.6) 1 (5.6) | 3 (7.9) | |
| Moderate | 11 (61.1) | 20 (52.6) | |
| Poor | 6 (33.3) | 15 (39.5) | |
| Harvested lymph nodes (n), median (IQR) | 12.5 (9-16) | 14.5 (10-20) | 0.521 |
| Lymph node metastasis, n (%) | 9 (50.0) | 25 (65.8) | 0.259 |
| Paraaortic lymph node metastasis (#16), n (%) | 1 (5.6) | 7 (18.4) | 0.199 |
| Resection Margin, n (%) | 0.487 | ||
| R0 | 18 (100.0) | 37 (97.4) | |
| R1 | 0 (0.0) | 1 (2.6) | |
| Vascular invasion (SMV/PV), n (%) | 9 (50.0) | 17 (44.7) | 0.712 |
| Perineural invasion, n (%) | 13 (72.2) | 20 (52.6) | 0.164 |
| Colonic invasion, n (%) | 0 (0.0) | 1 (2.6) | 0.487 |
| Tumor size (cm), median (IQR) | 4.3 (3.0-5.1) | 4.4 (3.4-6.6) | 0.408 |
| T stage | 0.445 | ||
| T1 | 0 (0.0) | 2 (5.3) | |
| T2 | 8 (44.4) | 13 (34.2) | |
| T3 | 10 (55.6) | 22 (57.9) | |
| T4 | 0 (0.0) | 1 (2.6) | |
| N stage | 0.502 | ||
| N0 | 9 (50.0) | 13 (34.2) | |
| N1 | 7 (38.9) | 18 (47.4) | |
| N2 | 2 (11.1) | 7 (18.4) | |
| AJCC 8th stage | 0.657 | ||
| IA-IB | 4 (22.2) | 7 (18.4) | |
| IIA-IIB | 12 (66.7) | 23 (60.5) | |
| III | 2 (11.1) | 8 (21.1) | |
| IV | 0 (0.0) | 0 (0.0) |
PPTP-SP: Partial pancreatic tail preserving-subtotal pancreatectomy; TP: Total pancreatectomy; PV/SMV: Portal vein and/or superior mesenteric vein; PDAC: Pancreatic ductal adenocarcinoma; IPMN: Intraductal papillary mucinous neoplasm; AJCC: American Joint Committee on Cancer; IQR: Interquartile range.